Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02466802 · ClinicalTrials.gov registry record · Phase 1
Study of Regorafenib and Sildenafil for Advanced Solid Tumors
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02466802 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 32 participants.
The verdict
NCT02466802, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase 1 study of sildenafil in combination with regorafenib in patients with progressive advanced solid tumors. A modified 3+3 dose escalation design will be conducted for the dose escalation of the treatment combination: additional patients will be enrolled at the MTD until a total of 12 patients have been treated at the MTD.
Interventions
- DRUG Regorafenib
- DRUG Sildenafil Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2019-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02466802
The ClinicalTrials.gov registry entry for NCT02466802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regorafenib is the first listed.
NCT02466802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02466802 about?
NCT02466802 is a clinical study titled "Study of Regorafenib and Sildenafil for Advanced Solid Tumors". This is a phase 1 study of sildenafil in combination with regorafenib in patients with progressive advanced solid tumors. A modified 3+3 dose escalation design will be conducted for the dose escalation of the treatment combination: additional patients will be enrolled at the MTD until a total of 12 ...
What is the current status of trial NCT02466802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-07-01. Estimated completion is 2019-01-28.
What interventions are being tested in trial NCT02466802?
The interventions under investigation include: Regorafenib (DRUG), Sildenafil Citrate (DRUG).
Who is sponsoring clinical trial NCT02466802?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.